Evidence map›Paper›PMID 28684396›Full record

ArticleDiabetes care2017

Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.

Toshiaki Ohkuma, Min Jun, Mark Woodward, Sophia Zoungas, Mark E Cooper, Diederick E Grobbee, Pavel Hamet, Giuseppe Mancia, Bryan Williams, Paul Welsh and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Association Between Type 2 Diabetes Mellitus and Heart Failure: A Retrospective Study from a Tertiary Care Diabetes Centre in India.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  10. Article
  11. Article
  12. Cardiac magnetic resonance versus echocardiography: An analysis examining risk reclassification by left ventricular ejection fraction and cost burden analysis.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2025
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 6 countries.

Toshiaki OhkumaThe George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-5463-1631
Min JunThe George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-1460-7535
Mark WoodwardThe George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia.
Sophia ZoungasThe George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia.
Mark E CooperDiabetic Complications Division, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Diederick E GrobbeeJulius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.
Pavel HametCentre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Giuseppe ManciaInstituto Auxologico Italiano, University of Milan-Bicocca, Milan, Italy.
Bryan WilliamsInstitute of Cardiovascular Sciences, University College London (UCL) and National Institute of Health Research UCL Hospitals Biomedical Research Centre, London, U.K.
Paul WelshInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.ORCID 0000-0002-1604-2593
Jonathan E ShawDepartment of Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Kazem RahimiThe George Institute for Global Health, University of Oxford, Oxford, U.K.
John ChalmersThe George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia chalmers@georgeinstitute.org.au.
ADVANCE Collaborative Group
The University of Sydney · AUBaker Heart and Diabetes Institute · AUUniversity of Glasgow · GBCentre Hospitalier de l’Université de Montréal · CANational Institute for Health Research · GBThe George Institute for Global Health · GBUniversity Medical Center Utrecht · NLUniversity of Milan · IT

Funding

Department of Health CDF-2013-06-012Medical Research Council MC_PC_13090Medical Research Council MR/N005813/1
6 · The paper itself

Abstract

objectiveThis study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes. RESEARCH DESIGN AND

methodsA nested case-cohort study was conducted in 3,098 participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

resultsA higher value of each biomarker was significantly associated with a higher risk of heart failure incidence or progression, after adjustment for major risk factors. The hazard ratios per 1-SD increase were 3.06 (95% CI 2.37, 3.96) for NT-proBNP, 1.50 (1.27, 1.77) for hs-cTnT, 1.48 (1.27, 1.72) for IL-6, and 1.32 (1.12, 1.55) for hs-CRP. The addition of NT-proBNP to the model including conventional risk factors meaningfully improved 5-year risk-predictive performance (C statistic 0.8162 to 0.8800; continuous net reclassification improvement [NRI] 73.1%; categorical NRI [<5%, 5-10%, >10% 5-year risk] 24.2%). In contrast, the addition of hs-cTnT, IL-6, or hs-CRP did not improve the prediction metrics consistently in combination or when added to NT-proBNP.

conclusionsOnly NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers.

Indexed as

AgedBiomarkersCholesterolCohort StudiesC-Reactive ProteinDiabetes Mellitus, Type 2Disease ProgressionFemaleFollow-Up StudiesGlycated HemoglobinHeart FailureHumansIncidenceInterleukin-6MaleMiddle AgedBiomarkersCholesterolC-Reactive ProteinGlycated HemoglobinIL6 protein, humanInterleukin-6Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)TriglyceridesTroponin T

Identifiers

PMID28684396
PMCPMC5892716
OpenAlexW2730830014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.